A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Carospir

Aldosterone Antagonist class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2017-08-04
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$3.53/unit
1 NDCs benchmarked, lowest of all strengths.
Average NADAC
$3.53
Across all dosage forms in distribution.
Highest NADAC
$3.53
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema7 entries indexed · 4 visible
What is Carospir used for?

Carospir is a Aldosterone Antagonist medication tracked in Medicare Part D.

Is there a generic for Carospir?

No. Carospir is brand-only with no generic equivalents currently in market.

How much does my plan pay for Carospir?

Across 329 Part D plans, Carospir averages $3.53/unit (NADAC). Lowest available: $3.53/unit. Highest in distribution: $3.53/unit.

Is Carospir on the FDA shortage list?

No. Carospir is not currently on the FDA Drug Shortage Database.

3 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Aldosterone Antagonist2 alternatives in D1
01
Eplerenone
Brand: Inspra
$0.329Lowest NADAC
8Generic mfrs
$41.6MCY24 Part D spend
Compare →
02
Spironolactone
Brand: Aldactone
$0.046Lowest NADAC
12Generic mfrs
$122.9MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (1 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.